SCHEMBL1315232

SCHEMBL1315232

CC(C)(C)OC(=O)c1ccc(-c2ccccc2)cc1NC(=O)c1ccc(Cl)nc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 1/20 0.51
KCNQ2 O43526 1/20 0.51
HDAC1 Q13547 3/20 0.49
ACLY P53396 3/20 0.49
MDM4 O15151 1/20 0.48
TP53 P04637 1/20 0.48
MDM2 Q00987 1/20 0.48
RAB9A P51151 3/20 0.44
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
KDM4E B2RXH2 3/20 0.44
HDAC3 O15379 2/20 0.43
HDAC2 Q92769 2/20 0.43
CYP1A2 P05177 2/20 0.43
KDR P35968 1/20 0.43
SERPINE1 P05121 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
LMNA P02545 2/20 0.42
MAPT P10636 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1316824 0.89 HDAC1 (0.50) HDAC1ACLYHDAC3HDAC2
SCHEMBL8162569 0.87 HDAC1 (0.52) KCNQ3KCNQ2HDAC1ACLYMDM4
SCHEMBL2573087 0.85 ACLY (0.67) KCNQ3KCNQ2HDAC1ACLYMDM4
SCHEMBL1316379 0.84 HDAC1 (0.47) HDAC1ACLYSMN1; SMN2HDAC3HDAC2
SCHEMBL1316008 0.84 GABRA1 (0.50) HDAC1ACLYHDAC3HDAC2
SCHEMBL2273488 0.82 SUCNR1 (0.52) HDAC1ACLYALDH1A1HDAC3HDAC2
SCHEMBL1317609 0.82 HDAC1 (0.47) HDAC1ACLYHDAC3HDAC2MAPK1
SCHEMBL2272718 0.82 HDAC2 (0.58) HDAC1RAB9AHDAC3HDAC2KMT2A
SCHEMBL1317192 0.82 HDAC1 (0.52) HDAC1ACLYHDAC2
SCHEMBL2275605 0.81 ACLY (0.53) HDAC1ACLYRAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
EP-2385036-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF Toyama Chemical Co., Ltd. (JP) 2011-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF COL14A1, COL2A1, COL1A1 KCNQ3 3909/4885KCNQ2 3905/4885HDAC1 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.